SCHEMBL1669583

SCHEMBL1669583

O=C(O)c1ccc(CCl)o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.67
POLB P06746 10/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
MAPK1 P28482 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.47
ALDH1A1 P00352 2/20 0.47
ESR1 P03372 1/20 0.47
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
RECQL P46063 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27484038 0.83 TDP1 (0.62) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
SCHEMBL3058890 0.83 TDP1 (0.45) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
SCHEMBL901472 0.82 TDP1 (0.72) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
SCHEMBL19801525 0.81 TDP1 (0.44) TDP1POLBSMN1; SMN2HSD17B10MAPT
SCHEMBL855813 0.81 HTT (0.44) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
SCHEMBL8610246 0.80 TDP1 (0.69) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
Sumiki'S Acid SCHEMBL50822 0.80 TDP1 (1.00) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
Sumiki'S Acid SCHEMBL29706392 0.80 TDP1 (1.00) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1
SCHEMBL18640579 0.79 CA1 (0.52) TDP1POLBSMN1; SMN2HSD17B10KMT2A
SCHEMBL18554594 0.78 TDP1 (0.67) TDP1POLBSMN1; SMN2HSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114057707-A Preparation method of N-4-indolyl-2-furancarboxamide compound 上海应用技术大学 2022-02-18 CN claimed
CN-111499878-A Antitumor polymer bonding medicine with synergistic effect and preparation method thereof 成都吱吖科技有限公司 2020-08-07 CN claimed
EP-3666764-A1 METHOD FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND FOR THE PREPARATION OF THE DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID Furanix Technologies B.V (NL) 2020-06-17 EP claimed
US-10392358-B2 Oxidation chemistry on furan aldehydes MICROMIDAS, INC. (US) 2019-08-27 US claimed
US-20180265488-A1 OXIDATION CHEMISTRY ON FURAN ALDEHYDES MICROMIDAS, INC. (US) 2018-09-20 US claimed
CN-108349920-A OXIDATION CHEMISTRY ON FURAN ALDEHYDES 微麦德斯公司 2018-07-31 CN claimed
WO-2017049211-A1 OXIDATION CHEMISTRY ON FURAN ALDEHYDES MICROMIDAS, INC. (US) 2017-03-23 WO claimed
CN-102666521-B Method for the preparation of 2,5-furandicarboxylic acid and for the preparation of the dialkyl ester of 2,5-furandicarboxylic acid FURANIX TECHNOLOGIES BV 2015-04-29 CN claimed
US-8865921-B2 Method for the preparation of 2,5-furandicarboxylic acid and for the preparation of the dialkyl ester of 2,5-furandicarboxylic acid FURANIX TECHNOLOGIES B.V. (NL) 2014-10-21 US claimed
US-20120271060-A1 METHOD FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND FOR THE PREPARATION OF THE DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID FURANIX TECHNOLOGIES B.V. (NL) 2012-10-25 US claimed
CN-102666521-A Method for the preparation of 2,5-furandicarboxylic acid and for the preparation of the dialkyl ester of 2,5-furandicarboxylic acid FURANIX TECHNOLOGIES BV 2012-09-12 CN claimed
EP-2486028-A1 METHOD FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND FOR THE PREPARATION OF THE DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID Furanix Technologies B.V. (NL) 2012-08-15 EP claimed
WO-2011043661-A1 METHOD FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND FOR THE PREPARATION OF THE DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID FURANIX TECHNOLOGIES B.V. (NL) 2011-04-14 WO claimed
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use CARMOT THERAPEUTICS INC. (US) 2025-11-04 US disclosed
EP-4563199-A2 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2025-06-04 EP disclosed
US-20250154137-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2025-05-15 US disclosed
US-4185147-A Production of amino-silicate compounds, condensation resinous products and foam BLOUNT DAVID H 1980-01-22 US disclosed
US-4146509-A ORGANIC AMMONIUM COMPOUNDS USED AS POLYMERIZATION CATALYSTS BAYER AKTIENGESELLSCHAFT (DE) 1979-03-27 US disclosed
US-4142030-A POLYURETHANE-SILICATE BAYER AKTIENGESELLSCHAFT (DE) 1979-02-27 US disclosed
US-4042536-A POLYISOCYANATE, SILICIC ACID, XEROGEL BAYER AKTIENGESELLSCHAFT (DT) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392358-B2 Oxidation chemistry on furan aldehydes AOX1, ALOX5, CBR1 TDP1 2488/4885POLB 2337/4885SMN1; SMN2 4547/4885
US-20250154137-A1 GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GCGR, GIPR TDP1 3659/4885POLB 4784/4885SMN1; SMN2 2952/4885
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use GLP1R, GCGR, GIPR TDP1 3659/4885POLB 4784/4885SMN1; SMN2 2952/4885
US-20180265488-A1 OXIDATION CHEMISTRY ON FURAN ALDEHYDES AOX1, ALOX5, CBR1 TDP1 2488/4885POLB 2337/4885SMN1; SMN2 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.